

3rd Annual Next Gen

# Immuno-Oncology Congress

14th - 15th March 2019 • London, UK



## Event overview

Over the past several years, many immuno-oncology modalities have emerged. These modalities, which include checkpoint inhibition, adoptive T-cell therapy (ACT), and cancer vaccines, are often designed to evade immune responses. This is a rapidly growing therapeutic field that embraces the concept of modulating the immune system to recognize tumor cells and target them for destruction. Our **Next-gen immuno-oncology congress** from past 2 years had gathered the professionals across the globe to deliver such latest developments.

Having completed two extremely successful editions, we are coming up with “3rd Annual Next-Gen Immuno-Oncology Congress” gathering the academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Immune Checkpoint Inhibitors and Adoptive Cellular Therapy.

## Key Highlights:

- ▶ Updates in development of monoclonal ADC’s and Bispecific Ab’s
- ▶ Immune Checkpoint Inhibitors and Combinations
- ▶ Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immunecheckpoint modulators)
- ▶ Biomarkers and Cancer Vaccines
- ▶ CAR-T cell therapy, Adoptive Cell Therapy
- ▶ Tumor microenvironment
- ▶ Oncolytic Viruses

## Who Should Attend?

Monoclonal and Bispecific Antibodies	Cell Therapy	Immune Checkpoint Inhibitors
<ul style="list-style-type: none"><li>• ADCs development Preclinical and Translational Oncology</li><li>• Oncology</li><li>• Bi-specifics- Preclinical and Translational</li><li>• Clinical development</li><li>• R&amp;D- Discovery and process</li><li>• PKPD/ADME/Tox</li><li>• Antibody Engineering</li><li>• Antibody therapeutics</li><li>• Physio-Chemistry /Synthetic Chemistry and/ Bio conjugation</li><li>• Bioanalysis</li></ul>	<ul style="list-style-type: none"><li>• Oncology</li><li>• Clinical development</li><li>• R&amp;D- discovery and process</li><li>• Discovery</li><li>• Target Validation</li><li>• Bioanalysis</li><li>• Therapeutic areas</li><li>• PKPD/ADME/Tox</li><li>• Biologics -antibody</li><li>• Cell-Based Immunotherapies</li><li>• Innate and adaptive immune cells</li><li>• Antibody engineering Tumour antigens and neoantigens</li></ul>	<ul style="list-style-type: none"><li>• Cancer immunotherapy</li><li>• Immune checkpoint targets</li><li>• Checkpoint inhibition</li><li>• Cellular therapy</li><li>• Clinical research</li><li>• Combination therapy</li><li>• Cancer Vaccines</li><li>• Preclinical and Translational Oncology R&amp;D</li><li>• Immune biomarkers</li><li>• Immunology</li><li>• Cancer biology</li><li>• Immuno-oncology</li><li>• Tumour-associated mechanisms of immune suppression</li></ul>

## Why Attend?

- Find out new case studies of antibody projects in development
- Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
- Explore the latest platforms and technologies on the market for development
- Discuss the best tool for your research in immune-oncology
- Share your work and achievements with your industry peers in the Poster Session

*3rd Annual Next Gen*

# Immuno-Oncology Congress

14th - 15th March 2019 • London, UK

## Advisory Panel

- **Eugene Zhukovsky**, Chief Scientific Officer, **Biomunex Pharmaceuticals, France**
- **Jeanette Leusen**, Group Leader, Tumor Immunology, **UMC Utrecht, Netherlands**
- **Sophia Karagiannis**, Head of Cancer Antibody Discovery and Immunotherapy, **King's College London, UK**

## Expert Speaker Panel

- **Eugene Zhukovsky**, Chief Scientific Officer, **Biomunex Pharmaceuticals, France**
- **Jeanette Leusen**, Group Leader, Tumor Immunology, **UMC Utrecht, Netherlands**
- **Sophia Karagiannis**, Head of Cancer Antibody Discovery and Immunotherapy, **King's College London, UK**
- **Thomas Valerius**, Professor-Department of stem cell and immunotherapy, **Kiel Life Science, Germany**
- **Lindy Durrant**, Professor, Cancer Immunotherapy, **The University of Nottingham, UK**
- **Steven Schellings**, Associate Director, Cellular Therapy, **Novartis, USA**
- **Matthias Friedrich**, Scientific Director, **Amgen, Germany**
- **Matthias Peipp**, Professor, Group Leader, **University of Kiel, Germany**
- **Livija Deban**, VP Immunology and Oncology, **Prokarium, UK**
- **Stefan Glueck**, Vice President, Global Medical Affairs, **Celgene, USA**
- **Hardev Pandha**, Professor of Medical Oncology, **University of Surrey, UK**
- **Kandeepan Ganeshaligam**, Oncology Executive Director, Therapeutic Area Head, **Merck, USA**
- **Laura Kenny**, Clinical Senior Lecturer, Medical Oncology, **Imperial College of London, UK**
- **Robert Hawkins**, Professor Cancer Research Campaign, **University of Manchester, UK**
- **Michelle Morrow**, Vice President, Preclinical and Translational Pharmacology, **F-Star Biotechnology Ltd, UK**
- **Thierry Wurch**, Director, External Research & Innovation, **Servier, France**
- **David Giljohann**, CEO, **Exicure, USA**
- **Sr. Representative, Cisbio**
- **Sr. Representative, Miltenyi Biotech**
- **Sr. Representative, Immudex**
- **Alex Blyth**, CEO, **LIFT BioSciences, UK**
- **Rob Allen**, Senior Director, Immunotherapy Programme, **Asterias Biotherapeutics, UK**
- **Andrew Sewell**, Professor, Division of Infection and Immunity, **Cardiff University, UK**
- **Michael Burnet**, Managing Director, **Synovo, Germany**
- **Heinz Lubenau**, Chief Operating Officer, Co-Founder, **Vaximm, Germany**
- **Zoe Johnson**, Head Translational Research & Early Development, **iOnctura, Switzerland**

For more information please contact **Amit** at [amit.shelke@marketsandmarkets.com](mailto:amit.shelke@marketsandmarkets.com) | +91 20 48598 284




3rd Annual Next Gen

# Immuno-Oncology Congress

14th - 15th March 2019 • London, UK

## Silver sponsors



## Sponsor/Exhibitor

MYRIAD  RBM<sup>®</sup>

exi**i**cure

**immuDEX**  
PRECISION IMMUNE MONITORING

## Supporting Association



3rd Annual Next Gen

# Immuno-Oncology Congress

14th - 15th March 2019 • London, UK

## Day 1 - Thursday 14<sup>th</sup> March, 2019

08:15 Registration  
08:55 Welcome note from MarketsandMarkets

STREAM A		STREAM B	
Monoclonal and Bispecific Antibodies		Immune Checkpoint Inhibitors & Combination Strategies	
9:00	Opening remarks from the Chairman	9:00	Opening remarks from the Chairman
9:05	<b>Keynote: Bispecific Antibodies to Deliver the Next Immuno-Oncology Breakthrough</b> <ul style="list-style-type: none"> <li>• mAb<sup>2</sup>™, a bispecific antibody format that allows a “plug and play” modular strategy</li> <li>• F-star product strategy to address heterogeneity of tumour phenotypes</li> <li>• In vitro and in vivo efficacy of F-star bispecific antibodies targeting oncology pathways</li> </ul> <b>Michelle Morrow, Vice President, Preclinical and Translational Pharmacology, F-Star Biotechnology Ltd, UK</b>	9:05	<b>Checkpoint inhibitors as a therapeutic strategy in Oncology</b> <ul style="list-style-type: none"> <li>• Harnessing the immune system to provide durable disease control and survival across a wide range of cancers</li> <li>• Innovative combination strategies to improve upon monotherapy activity and overcome resistance</li> <li>• Importance of patient selection in cancer immunotherapy</li> </ul> <b>Kandeepan Ganeshaligam, Executive Director, Oncology Therapeutic Area Head, Merck, USA</b>
9:35	Increasing specificity of targeting employing bispecific antibodies	9:35	CPI combination with chemotherapy and radiation
10:05	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	10:05	<b>Innate immune activators- spherical nucleic acid tlr9 in combination with checkpoint inhibitors</b> <ul style="list-style-type: none"> <li>• Spherical Nucleic Acids (SNA's) are 3D forms of DNA and RNA that enter cells naturally.</li> <li>• SNA's can be used to potently activate Tol-like-receptor (TLR) pathways.</li> <li>• Pre-clinical work has shown activity in Breast, Lung, Melanoma, and Colorectal cancers in combination with checkpoint inhibitors. Phase Ib/2 studies were begun in 2018 in patients.</li> </ul> <b>David Giljohann, CEO, Exicure, USA</b>
10:35	Morning Refreshments and Poster Presentations   One-to-One Networking Meetings		
Targeted Antibodies and Combinations		Pre-clinical & Translational Immuno-Oncology Developments	
11:25	Novel conjugation technologies-Payload and Linkers	11:25	Pre-clinical models for Immune Checkpoint Modulators
11:55	<b>Improving recruitment of myeloid effector cells for antibody therapy: impact of antibody isotype and CD47/SIRPa checkpoint blockade</b> <ul style="list-style-type: none"> <li>• Myeloid cells contribute to antibody efficacy</li> <li>• Human IgG2 and IgA isotypes selectively improve myeloid cell recruitment</li> <li>• Tumor cell killing by myeloid cells is enhanced by CD47/SIRPa interference</li> </ul> <b>Thomas Valerius, Professor-Department of stem cell and immunotherapy, Kiel Life Science, Germany</b>	11:55	Creating novel hypotheses and evaluation in translational research
12:25	<b>Bispecific antibody-based therapeutics to modulate T cell activation</b> <b>Thierry Wurch, Director, External Research &amp; Innovation, Servier, France</b>	12:25	Role of predictive biomarkers in patient enrichment strategies
12:55	Lunch and Poster Presentations   One-to-One Networking Meetings		



3rd Annual Next Gen

# Immuno-Oncology Congress

14th - 15th March 2019 • London, UK

δ

## Day 1 - Thursday 14<sup>th</sup> March, 2019

STREAM A	STREAM B	STREAM C
Monoclonal and Bispecific Antibodies	Immune Checkpoint Inhibitors	Cellular Therapy
New Antibody Formats	New Immune Checkpoints for Immunotherapy	Developments in CAR-T Cell Therapy and Vaccines
<p><b>13:55 Monoclonal antibody approaches for triple-negative breast cancer</b></p> <ul style="list-style-type: none"> <li>Highly-aggressive triple negative forms of breast cancer (TNBCs) lack validated targets and effective systemic therapies.</li> <li>We demonstrate that the tumor-associated antigen Folate Receptor alpha (FR<math>\alpha</math>) is overexpressed in subsets of TNBCs and may present a targetable molecule for monoclonal antibody therapy against TNBC.</li> <li>A monoclonal antibody recognizing FR<math>\alpha</math> triggered immune-dependent FR<math>\alpha</math>-expressing breast cancer cell death by healthy volunteer and breast cancer patient effector cells, and significantly restricted orthotopic TNBC line and patient-derived tumor xenograft growth.</li> </ul> <p><b>Sophia Karagiannis, Head of Cancer Antibody Discovery and Immunotherapy, King's College London, UK</b></p>	<p><b>13:55 PI3K<math>\delta</math>: A new era in immuno-oncology</b></p> <ul style="list-style-type: none"> <li>The scientific rationale for PI3K<math>\delta</math> as a novel immune checkpoint</li> <li>Preclinical development of a unique PI3K<math>\delta</math> inhibitor for immune-oncology</li> <li>Clinical development plans for IOA-244 as a monotherapy and in combination with traditional checkpoint blockade</li> </ul> <p><b>Zoe Johnson, Head Translational Research &amp; Early Development, iOnctura, Switzerland</b></p>	<p><b>13:55 Development of a New Generation of DNA Vaccines</b></p>
<p>14:35 <i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i></p>	<p>14:35 <i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i></p>	<p><b>14:35 Oral T-Cell Therapies for the Treatment of Cancer Patients</b> <b>Heinz Lubenau, Chief Operating Officer, Co-Founder, Vaximm, Germany</b></p>
<p><b>15:05 Break Out Session</b></p>	<p><b>15:05 Panel Discussion: Future of Biologics in Immune Checkpoint therapy</b></p>	<p><b>15:05 Break Out Session</b></p>
<p>15:35 <i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i></p>	<p>15:35 <i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i></p>	<p>15:35 <i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i></p>
<p><b>16:05 Evening Refreshments and Poster Presentations   One-to-One Networking Meetings</b></p>		
<p><b>16:55 Novel Bispecific PD-1 antibody therapeutic approach in solid tumours</b></p>	<p><b>16:55 Agonist checkpoint combination studies</b></p>	<p><b>16:55 Bispecific T-Cell engagers for cancer immunotherapy</b></p>
<p><b>17:25 Bicycle Drug Conjugate for treatment of solid tumours</b></p>	<p><b>17:25 Biomarkers for prognosis and prediction to immunotherapies</b></p>	<p><b>17:25 Synthetic Biology in Cellular Immunotherapy</b></p>

17:55 Closing remarks from the Chairman

18:00 End of Conference



3rd Annual Next Gen

# Immuno-Oncology Congress

14th - 15th March 2019 • London, UK

## Day 2 - Friday 15<sup>th</sup> March, 2019

08:15 Registration

08:55 Welcome note from MarketsandMarkets

STREAM A		STREAM B		STREAM C	
Monoclonal and Bispecific Antibodies		Immune Checkpoint Inhibitors		Cellular Therapy	
09:00	Opening remarks from the Chairman	09:00	Opening remarks from the Chairman	09:00	Opening remarks from the Chairman
New Antibodies Development and Tumor Microenvironment		Personalized Immunotherapy and Viral Therapies		Technologies for Personalized T Cell Receptor Engineered Cancer Immunotherapies	
09:05	Keynote: Understanding and overcoming resistance to monoclonal antibody therapy	09:05	Keynote: Improving efficacy of CPI's by selected combination therapy	09:05	Keynote: Precision Immunology for targeted therapy
09:35	Challenges in the clinical development of ADC's	09:35	Novel mRNA-based Immunotherapy Vaccines	09:35	<b>Using cancer killing neutrophils to destroy all solid tumours</b> <ul style="list-style-type: none"> <li>Targeted therapies don't work because tumours adapt and they don't</li> <li>Most people do not get cancer because of their innate immune systems – imagine if you could give that to cancer patient</li> <li>Introducing N-LiFT: Our game changing cancer killing neutrophils can destroy all solid tumours irrespective of mutation or strain</li> </ul> <a href="#">Alex Blyth, CEO, LiFT BioSciences, UK</a>
10:05	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	10:05	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	10:05	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>
10:35 Morning Refreshments and Poster Presentations   One-to-One Networking Meetings					
11:25	Recombinant antibodies for immunotherapy	11:25	Tumor neo-epitopes and their use in personalizing cancer immunotherapies	11:25	<b>Stress induced post translational modifications are good targets for cancer immunotherapy</b> <ul style="list-style-type: none"> <li>Stress including amino acid starvation, hypoxia, DNA damage or the unfolded protein response induces citrullination or the conversion of arginine to citrulline</li> <li>Tumours are under considerable stress and have high levels of autophagy</li> <li>Immunisation with citrullinated peptides induce cytotoxic CD4 T cells which effectively target tumours resulting in regression of bulky tumours</li> </ul> <a href="#">Lindy Durrant, Professor, Cancer Immunotherapy, The University of Nottingham, UK</a>
11:55	Understanding drug interaction potential for antibody drug conjugates in clinical development	11:55	Systematic Approaches to Identifying and Overcoming Resistance to Immune Checkpoint Inhibitors	11:55	Translational approach in developing right IO's
12:25	Role of Immune Activation Profiling in clinical trials	12:25	Oncolytic viruses in the era of Checkpoint Blockade	12:25	Treatment of MSI tumors and their superior response to immunotherapy
12:55 Lunch and Poster Presentations   One-to-One Networking Meetings					

*3rd Annual Next Gen*

# Immuno-Oncology Congress

14th - 15th March 2019 • London, UK

## Day 2 - Friday 15<sup>th</sup> March, 2019

STREAM A		STREAM B	
Monoclonal & Bispecific Antibodies		Immune Checkpoint Inhibitors and Combination Strategies	
13:55	Study of cytotoxic payloads-in vivo assays and efficacy testing	13:55	Role of Nanotechnology with a combinatorial approach for solid tumors
14:25	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	14:25	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>
14:55	Predicting the toxicity of Immuno-Oncology studies	14:55	Future opportunities in clinical development of ICI combinations
15:25	Closing remarks from the Chairman		
15:30	End of Conference		